Northland Capital Markets Starts Tilray (TLRY) at Outperform

Northland Capital Markets analyst Michael Grondahl initiates coverage on Tilray (NASDAQ: TLRY) with a Outperform rating and a price target of $35.00.

The analyst comments "We believe Tilray is uniquely positioned as the professional, strategic and high grade / high potency cannabis player as the pendulum is rapidly swinging towards greater acceptance and more medicinal and recreational use around the world."

For an analyst ratings summary and ratings history on Tilray click here. For more ratings news on Tilray click here.

Shares of Tilray closed at $26.87 yesterday.

You May Also Be Interested In

• Wedbush Starts Immunic Inc. (IMUX) at Outperform
• AEON Biopharma, Inc (AEON) PT Lowered to $1.20 at H.C. Wainwright
• Walmart (WMT) PT Lowered to $135 at Guggenheim